Immune Design Corp. (IMDZ) Receives $16.33 Average PT from Brokerages

Immune Design Corp. (NASDAQ:IMDZ) has earned a consensus rating of “Buy” from the six research firms that are presently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation and five have given a buy recommendation to the company. The average 1-year price target among brokers that have covered the stock in the last year is $16.33.

Several equities research analysts have recently weighed in on IMDZ shares. BidaskClub downgraded Immune Design Corp. from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 5th. Zacks Investment Research raised Immune Design Corp. from a “hold” rating to a “buy” rating and set a $11.00 price objective for the company in a report on Tuesday, July 18th. Jefferies Group LLC reissued a “buy” rating and issued a $18.00 price objective on shares of Immune Design Corp. in a report on Wednesday, June 28th. ValuEngine raised Immune Design Corp. from a “sell” rating to a “hold” rating in a report on Friday, August 11th. Finally, Royal Bank Of Canada started coverage on Immune Design Corp. in a report on Thursday, September 14th. They issued an “outperform” rating and a $20.00 price objective for the company.

In related news, major shareholder Leo Guthart purchased 10,000 shares of the firm’s stock in a transaction that occurred on Monday, September 18th. The stock was purchased at an average cost of $9.70 per share, with a total value of $97,000.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 20.70% of the stock is owned by company insiders.

Hedge funds and other institutional investors have recently modified their holdings of the stock. Renaissance Technologies LLC lifted its holdings in shares of Immune Design Corp. by 170.0% during the first quarter. Renaissance Technologies LLC now owns 111,740 shares of the biotechnology company’s stock worth $760,000 after purchasing an additional 70,351 shares during the period. Victory Capital Management Inc. lifted its holdings in shares of Immune Design Corp. by 2.1% during the second quarter. Victory Capital Management Inc. now owns 1,977,564 shares of the biotechnology company’s stock worth $19,281,000 after purchasing an additional 40,010 shares during the period. Bain Capital Public Equity Management LLC lifted its holdings in shares of Immune Design Corp. by 393.1% during the second quarter. Bain Capital Public Equity Management LLC now owns 389,400 shares of the biotechnology company’s stock worth $3,797,000 after purchasing an additional 310,433 shares during the period. Trexquant Investment LP acquired a new stake in shares of Immune Design Corp. during the first quarter worth $183,000. Finally, Wells Fargo & Company MN lifted its holdings in shares of Immune Design Corp. by 46.5% during the first quarter. Wells Fargo & Company MN now owns 148,887 shares of the biotechnology company’s stock worth $1,012,000 after purchasing an additional 47,266 shares during the period. 51.46% of the stock is owned by hedge funds and other institutional investors.

Immune Design Corp. (NASDAQ:IMDZ) remained flat at $11.00 during trading on Monday. The company had a trading volume of 75,578 shares. Immune Design Corp. has a one year low of $4.50 and a one year high of $13.05. The firm’s 50 day moving average price is $10.21 and its 200-day moving average price is $8.51. The firm’s market cap is $281.81 million.

Immune Design Corp. (NASDAQ:IMDZ) last posted its quarterly earnings data on Wednesday, August 2nd. The biotechnology company reported ($0.54) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.65) by $0.11. The business had revenue of $0.73 million during the quarter, compared to the consensus estimate of $1.50 million. Immune Design Corp. had a negative return on equity of 59.14% and a negative net margin of 324.33%. On average, analysts predict that Immune Design Corp. will post ($2.34) EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Immune Design Corp. (IMDZ) Receives $16.33 Average PT from Brokerages” was first published by Ticker Report and is the property of of Ticker Report. If you are accessing this story on another site, it was copied illegally and republished in violation of US & international trademark & copyright law. The correct version of this story can be read at https://www.tickerreport.com/banking-finance/2955860/immune-design-corp-imdz-receives-16-33-average-pt-from-brokerages.html.

About Immune Design Corp.

Immune Design Corp. is a clinical-stage immunotherapy company. The Company is focused on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Company has engineered its technologies to activate the immune system’s natural ability to create tumor-specific cytotoxic T cells (CTLs) to fight cancer.

Receive News & Ratings for Immune Design Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Design Corp. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2017 Ticker Report. Google+.